Cited by 109Virus-based gene therapy researchRNA Interference and Gene DeliveryBarrier Structure and Function Studies

Methods for Gene Transfer to the Central Nervous System

Open access
Kantor, Boris, Bailey, Rachel M., Wimberly, Keon, Kalburgi, Sahana N., Gray, Steven J.·2014·Advances in Genetics

Abstract

Gene transfer is an increasingly utilized approach for research and clinical applications involving the central nervous system (CNS). Vectors for gene transfer can be as simple as an unmodified plasmid, but more commonly involve complex modifications to viruses to make them suitable gene delivery vehicles. This chapter will explain how tools for CNS gene transfer have been derived from naturally occurring viruses. The current capabilities of plasmid, retroviral, adeno-associated virus, adenovirus, and herpes simplex virus vectors for CNS gene delivery will be described. These include both focal and global CNS gene transfer strategies, with short- or long-term gene expression. As is described in this chapter, an important aspect of any vector is the cis-acting regulatory elements incorporated into the vector genome that control when, where, and how the transgene is expressed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/b978-0-12-800149-3.00003-2

Cites

338 of 338 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AAV vectors support long-term, non-toxic gene expression for up to 8 years in non-human primates.

    “AAV vectors support long-term, non-toxic gene expression for up to 8 years in non-human primates.1–3”

    From Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism (2016) · cites this paper as [3]

    Section 2.2 (page not provided) reports AAV-delivered expression lasting at least 6 years in primates; it assigns the 8-year figure to dogs, not primates. The same section describes AAV vectors as having no known associated pathologies and causing a very mild immune response, which supports the safety characterization but does not establish an eight-year non-toxic outcome in primates. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. Bernard Roizman DK 2001 Herpes simplex viruses and their replication 4 Fields Virology Philadelphia, PA Lippincott Williams & Wilkins
  2. Hu JC Coffin RS 2003 Oncolytic herpes simplex virus for tumor therapy International Review of Neurobiology 55 165 184 12968536

Cited by

Sorted by citations

Authors
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J.
Affiliations
  • University of South Carolina (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Gray, Steven J.
Venue
Advances in Genetics
Publisher
Elsevier
Published
2014
Volume
87
Pages
125-197
ISSN
0065-2660 (ISSN-L)
OpenAlex
W2414165069
Cited by
109
References
338
Citations by year
2026: 3 · 2025: 11 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 17 · 2020: 9 · 2019: 6 · 2018: 11 · 2017: 9 · 2016: 14 · 2015: 1
FWCI
20.49
Type
book chapter
Language
en
Open access
Locations
  • Advances in genetics (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (P30NS045892, R01NS087175)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
gene delivery vectors, plasmid vectors, retroviral vectors, adeno-associated virus vectors, adenoviral vector, herpes simplex virus vectors, cis-regulatory elements, transgene expression
MeSH terms
Adenoviridae, Central Nervous System, Genetic Vectors, Humans, Genetic Therapy, Gene Expression, Lentivirus, Gene Transfer Techniques, Simplexvirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review